Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 15/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | VCP | P55072 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | JMJD1C | Q15652 | 1/20 | 0.45 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30443744 | 0.88 | GRIN2B (0.50) | GRIN2BCYP11B2HRH4 | |
| SCHEMBL2834000 | 0.82 | ASPH (0.55) | GRIN2BVCPKDM4EKDM5AJMJD1C | |
| SCHEMBL5914219 | 0.77 | VCP (0.48) | GRIN2BCYP11B2VCP | |
| SCHEMBL19476325 | 0.77 | MERTK (0.54) | GRIN2BCYP11B2HRH4 | |
| SCHEMBL3646509 | 0.76 | CYP11B2 (0.74) | GRIN2BCYP11B2VCP | |
| SCHEMBL25387245 | 0.75 | S1PR1 (0.47) | GRIN2BCYP11B2KDM4EHRH4 | |
| SCHEMBL30443679 | 0.75 | S1PR1 (0.47) | GRIN2BCYP11B2KDM4EHRH4 | |
| SCHEMBL19477186 | 0.75 | CCNT1 (0.52) | GRIN2BCYP11B2 | |
| SCHEMBL5477983 | 0.74 | GRIN2B (0.40) | GRIN2BCYP11B2VCP | |
| SCHEMBL8292639 | 0.74 | GRIN2B (0.40) | GRIN2BCYP11B2VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-10-10 | — | — | US | disclosed |
| EP-4209485-A1 | COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF | Innovstone Therapeutics Limited (CN) | 2023-07-12 | — | — | EP | disclosed |
| CN-116113626-A | Compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2022048631-A1 | COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | PRMT5, PRMT1, PRMT6 | GRIN2B 3716/4885CYP11B2 2976/4885VCP 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.